Royalty Pharma's Total Assets for the quarter that ended in Dec. 2023 was $16,382 Mil.
During the past 12 months, Royalty Pharma's average Total Assets Growth Rate was 5.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 4.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 10.00% per year.
During the past 7 years, Royalty Pharma's highest 3-Year average Total Assets Growth Rate was 17.90%. The lowest was 4.20%. And the median was 7.30%.
Total Assets is connected with ROA %. Royalty Pharma's annualizedROA % for the quarter that ended in Dec. 2023 was 12.27%. Total Assets is also linked to Revenue through Asset Turnover. Royalty Pharma's Asset Turnover for the quarter that ended in Dec. 2023 was 0.04.
Royalty Pharma Total Assets Historical Data
The historical data trend for Royalty Pharma's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Royalty Pharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (NAS:RPRX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Royalty Pharma's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Royalty Pharma Total Assets Related Terms
Thank you for viewing the detailed overview of Royalty Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Royalty Pharma (Royalty Pharma) Business Description
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RPRX has been successfully added to your 